Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.90
-2.0%
$12.40
$10.45
$21.69
$4.92B0.62721,030 shs294,386 shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$136.24
+0.4%
$143.06
$55.92
$157.13
$4.35B1.41492,646 shs433,891 shs
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14.54
-0.4%
$14.86
$8.26
$19.41
$1.24B-0.011.30 million shs1.77 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$87.20
-0.5%
$79.81
$41.50
$90.32
$4.39B-2.63856,334 shs1.19 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-2.00%+0.14%+20.74%+15.19%-17.11%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
+0.35%+0.22%-6.38%+34.94%+34.64%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-0.41%+3.19%+6.60%+5.98%+28.28%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-0.50%+6.90%+9.85%+24.61%+79.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.0792 of 5 stars
3.12.00.00.02.01.72.5
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
1.3173 of 5 stars
2.51.00.00.03.20.80.6
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.265 of 5 stars
4.50.00.00.01.84.20.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.2742 of 5 stars
3.51.00.04.63.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.17
Hold$15.4511.18% Upside
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2.90
Moderate Buy$137.300.78% Upside
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.00
Buy$26.8984.93% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.09
Buy$108.7024.66% Upside

Current Analyst Ratings Breakdown

Latest LQDA, BLCO, IRTC, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$160.00 ➝ $147.00
7/11/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$105.00 ➝ $121.00
7/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$13.00 ➝ $15.00
7/8/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.50 ➝ $16.00
6/23/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
6/23/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$110.00
6/12/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.00
6/11/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$130.00 ➝ $160.00
6/11/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $23.00
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
6/2/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.03$1.87 per share7.42$18.57 per share0.75
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$591.84M7.35N/AN/A$2.90 per share46.98
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14M88.79N/AN/A$0.91 per share15.98
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.481.57-7.50%2.62%1.28%7/30/2025 (Estimated)
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$113.29M-$3.14N/AN/AN/A-15.90%-101.04%-9.55%7/30/2025 (Estimated)
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)

Latest LQDA, BLCO, IRTC, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.53N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.43N/AN/AN/A$3.90 millionN/A
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.85N/AN/AN/A$3.91 millionN/A
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
5/8/2025Q1 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
5/1/2025Q1 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
7.47
5.71
5.58
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
2.08
2.93
2.91
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
19.64
19.64

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
64.54%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
1.10%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
26.50%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.80 million351.12 millionOptionable
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2,00031.92 million31.57 millionOptionable
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
5085.49 million62.83 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million47.17 millionOptionable

Recent News About These Companies

11 Best Performing Mid Cap Stocks So Far In 2025
FY2025 EPS Estimates for SLNO Raised by Cantor Fitzgerald
Soleno Therapeutics: Fairly Valued Despite M&A Expectations

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.90 -0.28 (-1.97%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$13.91 +0.01 (+0.07%)
As of 07/18/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

iRhythm Technologies stock logo

iRhythm Technologies NASDAQ:IRTC

$136.24 +0.48 (+0.35%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$136.28 +0.04 (+0.03%)
As of 07/18/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Liquidia Technologies stock logo

Liquidia Technologies NASDAQ:LQDA

$14.54 -0.06 (-0.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$14.74 +0.20 (+1.38%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$87.20 -0.44 (-0.50%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$87.16 -0.05 (-0.05%)
As of 07/18/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.